These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 35453571)
1. Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. David S; Tan J; Siva S; Karroum L; Savas P; Loi S Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453571 [TBL] [Abstract][Full Text] [Related]
2. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Akanda ZZ; Neeson PJ; John T; Barnett S; Hanna GG; Miller A; Jennens R; Siva S Transl Lung Cancer Res; 2021 Jun; 10(6):2766-2778. PubMed ID: 34295676 [TBL] [Abstract][Full Text] [Related]
3. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado? Xing D; Siva S; Hanna GG Clin Oncol (R Coll Radiol); 2019 Jul; 31(7):432-443. PubMed ID: 31005381 [TBL] [Abstract][Full Text] [Related]
4. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488 [No Abstract] [Full Text] [Related]
5. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760 [TBL] [Abstract][Full Text] [Related]
6. SABR in oligometastatic breast cancer: Current status and future directions. Stewart R; White M; Tan J; Siva S; Karroum L; David S Breast; 2021 Dec; 60():223-229. PubMed ID: 34739890 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. Masucci GV; Wersäll P; Kiessling R; Lundqvist A; Lewensohn R J Transl Med; 2012 May; 10():104. PubMed ID: 22616654 [TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients. Morales-Orue I; Zafra-Martin J; Garcia L; Chicas-Sett R; Castilla-Martinez J; Cabezon MA; Burgos J; Lloret M; Lara PC Transl Cancer Res; 2020 Jan; 9(Suppl 1):S197-S206. PubMed ID: 35117963 [TBL] [Abstract][Full Text] [Related]
9. Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy. Ratnayake G; Reinwald S; Edwards J; Wong N; Yu D; Ward R; Smith R; Haydon A; Au PM; van Zelm MC; Senthi S Radiother Oncol; 2022 Aug; 173():299-305. PubMed ID: 35772575 [TBL] [Abstract][Full Text] [Related]
10. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review. Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087 [TBL] [Abstract][Full Text] [Related]
12. Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions. Zayed S; Louie AV; Breadner DA; Palma DA; Correa RJM Ther Adv Med Oncol; 2023; 15():17588359231183668. PubMed ID: 37435562 [TBL] [Abstract][Full Text] [Related]
13. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy. Dohopolski M; Iyengar P Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460 [TBL] [Abstract][Full Text] [Related]
14. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Park SS; Dong H; Liu X; Harrington SM; Krco CJ; Grams MP; Mansfield AS; Furutani KM; Olivier KR; Kwon ED Cancer Immunol Res; 2015 Jun; 3(6):610-9. PubMed ID: 25701325 [TBL] [Abstract][Full Text] [Related]